Amgen Inc. (NASDAQ:AMGN) is seeing a significant rise in its stock price, thanks to positive news in the healthcare sector.
Today, Amgen's stock is up 3.21%, closing at CA$439.80. This increase follows recent announcements about the company's advancements in treatments for neuroendocrine prostate cancer and other age-related conditions.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$223.19B
P/E
25.6x
Div. yield
2.35%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+3.15%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 15, 2026
Wall Street analysts forecast AMGN stock price to fall 7.4% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$394.77
-7.4% Upside
Previously C$393.91 on Oct 14, 2026
Current Price
C$426.11
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
41.3%
Annualized
90-Day Vol
32.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$509.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$452.24 | C$392.15 – C$521.55 |
| 60 trading days | C$479.98 | C$392.33 – C$587.22 |
| 90 trading days | C$509.42 | C$397.94 – C$652.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are feeling more confident in Amgen, encouraged by the company's promising pipeline and strong performance in recent trials, suggesting a solid growth path ahead.
3.21% Increase in Stock Price
Advertisement
Amgen's stock has been on a strong upward trend, gaining 9.41% over the past 30 days and 15.22% over the last 90 days, reflecting positive investor sentiment.
Bull case
The increasing awareness of neuroendocrine prostate cancer as a serious health issue is broadening the market for Amgen's therapies, including Tarlatamab (AMG 757). Additionally, the company’s solid historical performance and positive trial results for Tezspire in eosinophilic esophagitis support its growth story.
Bear case
Despite the current rise, some analysts believe Amgen's stock might be overvalued at this price point. They express concerns about execution risks in its obesity treatment pipeline and competition from established players.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
